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Background: Cystatins are natural endogenous inhibitors of
cysteine proteases universally involved into development of dif-
ferent tumors. Tumor growth and metastazing include increased
consumption of these inhibitors, followed by decreased level of
cystatins and dysregulation of proteases/protease inhibitors sys-
tem. However, the biological role of individual cystatins is still
not clear. The most known cystatin C was shown to relate to
some types of tumor development. Cystatins include a group of
intracellular cystatins (belonging to type 1) and extracellular cys-
tatins (type 2), among them cystatins C, D, E/M, F, G, S, SN and SA,
which functions were not studied enough. It was suggested that
cystatin SN was responsible in regulation of tumor growth locally.
The aim: To investigate cystatin C and cystatin SN concentra-
tions in biological fluids of patients with intraocular melanoma
as tumor biomarkers and possible therapy targets.
Materials and methods: The patients with melanoma chori-
oidea (57 patients; among them woman 36, men 21; aged from
28 to 80, of middle age of 56.6 ± 2.4 years) were under investiga-
tion. In all cases the pathological process involved one eye. The
control group consisted of 37 healthy persons (volunteers), med-
ical personnel in clinic and students, aged from 20 to 49 years; the
middle age 31 ± 4.1 years); 7 patients with age-related cataract
aged from 57 to 80 (middle age 71 ± 2.6 years; man 3, woman 4).
The biological fluids studied: tears, intraocular fluid (obtained
during operation) and blood serum. In all cases investigation
was made according to informed agreement of patients and con-
trol group members. Cystatins concentration was measured by
ELISA kits: for Cystatin C (BioVendor, Chechia) and for cystatin
SN with help of Human Cystatin SN (CST1) Elisa Kit Cusabio,
China. Statistical analysis was made by non-parametric statistic
test of Kruskal–Wallis, for correlations – Spearman test. The
difference between groups studied was considered significant
p < 0.05.
Results: Increased serum level of cystatin C was revealed in
patients with melanoma chorioides (1023.5 ± 78.9 ng/ml,
p = 0.019) compared with the control (809.9 ± 146.8 ng/ml). In tears
of patients with melanoma chorioidea, cystatin C concentration
(441.7 ± 14.5 ng/ml) had a tendency to increase as compared to
the data obtained in tears of the control group (287.5 ± 20.01 ng/ml)
as well as the cystatin C level of intraocular fluid of these patients
vs the control group (p < 0.1). Cystatin SN concentration in serum
of patients with melanoma chorioidea (1.45 ± 0.30 ng/ml) was
lower vs the control group (3.12 ± 0.32 ng/ml, p = 0.0038), as well
as Cystatin SN level in intraocular fluid (1.43 ± 0.10 ng/ml) vs the
control (2.60 ± 0.60 ng/ml, p < 0.05). There was no difference in
cystatin SN concentration in tears of patients and control group.
Conclusion: In serum of control (healthy) group, cystatin C
concentration is significantly higher than cystatin SN level in
serum, tears and intraocular fluid. The reverse correlation was
revealed between the level of these inhibitors in serum, that is
suggested their possible interaction. In melanoma patients the
reciprocal changes in cystatin C and cystatin SN were shown:
increased cystatin C and decreased cystatin SN level in all
biological fluids studied. On the basis of cystatins distribution in
biological fluids of patients one can suggest their involvement
in pathological process as system reaction of organism on tumor
development.
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Background: To determine diagnostic importance of DNA
methylation in patients with chronic atrophic gastritis and induc-
tion of ‘‘Correa” cascade for gastric cancer prevention.
Material and methods: This present study included 80 patients
with chronic atrophic gastritis associated with Helicobacter pylori.
Diagnoses were confirmed by endoscopic, morphologic, serologic
examinations. Age of patients varied from 17 to 78 years old.
There were 52 (65%) males and 28 (35%) females. The control
group consisted of 32 patients with morphological verified diag-
nosis of stage I–II gastric cancer. Examination with the purpose
to determine hypermethylation of DNA was performed simulta-
neously in biopsy materials and blood plasma. Provoking factors
of hypermethylation in 4 tumors’ genes, APE, E-Cadherin,
T1MP3, hMLHI were determined by quantitative methylation with
use of Polymerase Chain Reaction. To evaluate the level of methy-
lation we compared the analysis’ results of biopsy and blood
plasma tests. Blood serum samples and biopsy specimens were
collected at diagnosis until the therapy is started. All patients
with chronic atrophic gastritis infected with H. pylori underwent
anti-H. pylori therapy according to the protocol. Chronic atrophic
gastritis was found at morphologic examination in 40 (50%)
patients according to ‘‘Correa” cascade. 36 (45%) patients had
intestinal metaplasia, and 4 (5%) patients had dysplasia. Reaction
was considered to be positive in cases, when the level of methy-
lation in genes listed above was higher in blood serum than in
biopsy materials.
Results: High concentrations of methylated APE, T1MP3 and
hMLIH in genes were found in blood serum of 8 (10%) patients.
In the control group, all 32 patients with gastric cancer had high
methylation level in blood serum. In the remaining 72 (90%)
patients, no high concentration of DNA methylation was found.
After the 2-nd course of anti-H. pylori therapy, patients underwent
morphologic and endoscopic examinations according to the
protocol. Eradication of H. pylori was determined in 86% patients
who received therapy. Intestinal metaplasia decreased from 45%
to 25% (20 patients). Mild dysplasia was found in 1.2% of cases.
Repeated analysis of methylation level showed its decrease after
anti-H. pylori therapy in 4 (50%) out of 8 patients.
Conclusion: Genetic tests show that DNA methylation in
patients with chronic atrophic gastritis has high diagnostic
importance. Anti-H. pylori therapy at the different stages of
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‘‘Correa” cascade has high level of induction in transforming into
non invase gastric cancer.
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The Chelyabinsk region is a classic example of the
technologically-saturated region. The index of pollution of
atmospheric air is estimated as high. The Chelyabinsk region is
among the areas of increased cancer risk. The incidence of head
and neck cancer is steadily increasing, accounting for 20–25% of
all cancer cases in Russia. Oropharyngeal cancer makes up 5.1%
of all cancers.
Materials and methods: The object of the study was the
population of the Chelyabinsk region. The analysis was
conducted according to the materials of the annual reports of
the statistics department of the Chelyabinsk district oncology
dispensary.
Results: Out of the total cancer cases for the population of Che-
lyabinsk region in 2014, oro-pharyngeal cancer comprised 2.06%,
including cancers of the lip (0.35%), tongue (0.47%), major salivary
glands (0.22%), other unspecified parts of the mouth (0.52%),
oropharynx (0.33%), nasopharynx (0.1%) and hypopharynx
(0.07%). From 2008 to 2014, the incidence of oral and pharyngeal
cancer among adult population of Chelyabinsk city and
Chelyabinsk region showed an 8.8% increase. In the period from
2011 to 2014, the incidence of oral and pharyngeal cancer tended
to increase, the overall rise being 71.8%. It should be noted that
the oral and pharyngeal cancer incidence was 3 times higher in
males than in females in 2013 and 2 times higher in 2014.
One of the main indicators that determine the prognosis for the
development of cancer, is the extent of tumor at time of
diagnosis.
Out of the total cancer cases for the population of Chelyabinsk
region in 2014, cancer of the oral cavity comprised 1.33%, pharyn-
geal cancer 0.6%, lip cancer 0.13%, ranking the 17th, 19th and 24th
place respectively among the causes of death from all cancers.
Analyzing the dynamics of mortality from cancer of the oral cav-
ity and pharynx during the study period, it was revealed that the
mortality rate increased by 0.7%.
Conclusion: Head and neck tumors are a rare group of clini-
cally and biologically diverse neoplastic diseases. Among the res-
idents of the Chelyabinsk region, men are 2–3 times more
susceptible to cancer of the oral cavity and pharynx than women.
High mortality rate is due to late referral of patients to specialized
clinics; most head and neck cancer patients are diagnosed at
advanced stages.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.026
P83
Biochemical markers and clinical symptoms in pancreatic cancer
patients
O. Ephimovaa,*, I. Grigorevaa,c, T. Romanovaa, Y. Raginoa,
T. Suvorovab, N. Tovb. a Institution of Internal and Preventive
Medicine, Novosibirsk, Russian Federation, bNovosibirsk State Medical
University, Russian Federation, cNovosibirsk State University,
Novosibirsk, Russian Federation
⇑
Corresponding author.
Background: To evaluate the clinical symptoms in pancreatic
cancer patients (PCa) and compare some biochemical blood
serum parameters in patients with different pathology of the
pancreas (PCa, acute (OP) and chronic pancreatitis (CP)).
Materials and methods: During a one-time clinical research on
the type of ‘‘series of cases” 130 patients were examined
(42 patients with OP, 81 – CP and 7 patients with PCa). The diagno-
sis of PCa, OP, CP was verified by clinical and instrumental
methods. Glucose, cholesterol, triglyceride and bilirubin serum
levels were determined by ELISA.
Results: The mean age of patients with PCa was 63.6
± 4.9 years, morbidity duration of PCa – 3.5 ± 1.1 months. Among
patients with PCa, 83.3% of people – smoked, 16.7% – smoked
every day. Half of the respondents PCa patients noted that over
the last year they did not drink alcohol; 16.7% of people – drank
alcohol several times a year, and 33.3% of patients consumed
alcohol 1–2 times a month. BMI of PCa patients was equal to
26.3 ± 3.5 kg/m2, in OP patients – 23.8 ± 1.0 kg/m2, in CP patients
– 26.3 ± 0.6 kg/m2, p > 0.05. In this case, 85.7% of PCa patients
noted a significant decrease in body weight (11.7 ± 6.0 kg) for
3–4 months after the onset of symptoms. There was no pain in
42.8% of PCa patients, and frequent pain noted only in 28.6% of
persons. Among CP patients, frequent and persistent pain noted
in 65.5% of patients and among OP patients in 48.6% of cases.
All PCa patients experienced pain in the right upper quadrant.
Pain was of low intensity in 75% of cases and moderate in 25%
of cases. Elimination of pain was observed in half of the PCa
patients, and 1/4 of patients continued to experience pain. Epi-
sodes of nausea and vomiting noted in 25% of PCa patients.
Bloated feeling in the stomach and overflow were noted in
42.8% of the all surveyed PCa persons. The level of glucose in
PCa patients exceeded the normal limits and was significantly
higher compared to that in OP and CP patients (8.5 ± 1.4 mmol/L,
5.4 ± 0.3 and 5.1 ± 0.1 mmol/L, respectively, p < 0.05). Hyperbiliru-
binemia was detected in PCa patients – 89.9 ± 27.5 lmol/L; in OP
and CP patients bilirubin levels were 32.2 ± 11.0 and 13.4
± 1.8 lmol/L, respectively, which were significantly lower than
those in patients with PCa, p < 0.05. Triglyceride levels did not
differ in patients with different pancreas diseases (PCa – 1.7 ± 0.3,
CP – 1.86 ± 0.1 and OP –1.88 ± 0.11 mmol/L, p > 0.05). However,
the total cholesterol in CP patients was significantly higher
than that in PCa and OP patients (5.8 ± 0.1, 5.0 ± 0.6 and
4.1 ± 0.2 mmol/L, p < 0.05). In PCa patients, the elevated levels of
some markers of cholestasis and hepatocyte injury were
also found: ALP – 185.0 ± 12.7 IU/L, ALT – 108.4 ± 33.5 IU/L,
AST – 85.3 ± 31.5 IU/L, amylase – 44.9 ± 14.9 IU/L, fibrinogen –
2696.6 ± 398.6 g/L.
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